AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8330548 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic sclerotherapy
Number of subjects: 82
Study 8330548 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sclerotherapy)
Number of subjects: 82
Study 3487938 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal radiography using two different air‐contrast techniques
Number of subjects: 48
Study 3487938 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal radiography
Number of subjects: 48
Study 31816432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 44
Study 31816432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 44
Study 29843811 — intervention group
Group type: EXPERIMENTAL
Intervention: DCVax-L
Number of subjects: 331
Study 29843811 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone (placebo)
Number of subjects: 331
Study 26919037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IA)
Number of subjects: 60
Study 26919037 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (EA)
Number of subjects: 60
Study 26919037 — intervention group
Group type: COMPARATOR
Intervention: Both IA and EA
Number of subjects: 60
Study 24282101 — intervention group
Group type: EXPERIMENTAL
Intervention: True Moxibustion (TM)
Number of subjects: 16
Study 24282101 — intervention group
Group type: COMPARATOR
Intervention: Sham Moxibustion (SM)
Number of subjects: 16
Study 21609256 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-flap approach (SFA)
Number of subjects: 14
Study 21609256 — intervention group
Group type: COMPARATOR
Intervention: Double-flap approach (DFA)
Number of subjects: 14
Study 20090776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (CF) 1052 mg day(‐1) for 6 weeks
Number of subjects: 52
Study 18422916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketomousse (1% ketoconazole)
Number of subjects: 46
Study 18422916 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole cream 2%
Number of subjects: 46
Study 16187171 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (3 mg/kg)
Number of subjects: 20
Study 16187171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14959904 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 epinephrine
Number of subjects: 20
Study 14959904 — intervention group
Group type: COMPARATOR
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 20
Study 10229004 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 150 U/kg per week
Number of subjects: 44
Study 10229004 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 450 U/kg per week
Number of subjects: 44
Study 10229004 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 44
Study 10229004 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (both doses)
Number of subjects: 44
Study 9019822 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant histochrome
Number of subjects: 66
Study 9019822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 1906791 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg twice daily for 7 days starting on day 1 of the contraceptive cycle
Number of subjects: 12
Study 1906791 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no temafloxacin)
Number of subjects: 12
Study 1906791 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin
Number of subjects: 12
Study 6654698 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g/d of sodium DL‐3‐hydroxybutyrate
Number of subjects: 32
Study 6654698 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic glucose
Number of subjects: 32
Study 30734967 — intervention group
Group type: EXPERIMENTAL
Intervention: Community resource persons trained to provide culturally appropriate information on family planning
Number of subjects: 484
Study 30734967 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 484
Study 29437667 — intervention group
Group type: EXPERIMENTAL
Intervention: WAVES intervention (healthy lifestyle programme)
Number of subjects: 1467
Study 29437667 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 1467
Study 26820355 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening and optimal management of comorbidities
Number of subjects: 360
Study 26820355 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study 24448036 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly practice (once/week for four consecutive weeks)
Number of subjects: 110
Study 24448036 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive day practice (once/day for four consecutive days)
Number of subjects: 110
Study 24448036 — intervention group
Group type: COMPARATOR
Intervention: Standard group (control; no practice sessions)
Number of subjects: 110
Study 22858715 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg OTO-104
Number of subjects: 44
Study 22858715 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg OTO-104
Number of subjects: 44
Study 22858715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19321493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg, up to 30 mg)
Number of subjects: 96
Study 19321493 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 17563999 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrate
Number of subjects: 0
Study 15466981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tests of total and percent free PSA
Number of subjects: 2069
Study 15466981 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PSA
Number of subjects: 2069
Study 15466981 — intervention group
Group type: COMPARATOR
Intervention: PSA > 4.0 ng/mL
Number of subjects: 2069
Study 11353359 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anesthetics (EMLA)
Number of subjects: 23
Study 11353359 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 23
Study 11353359 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment groups (EMLA and Music)
Number of subjects: 23
Study 11353359 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study 9443116 — intervention group
Group type: EXPERIMENTAL
Intervention: High-meat group (HMG) - mean meat content of 27 g/day
Number of subjects: 41
Study 9443116 — intervention group
Group type: COMPARATOR
Intervention: Low-meat group (LMG) - mean meat content of 10 g/day
Number of subjects: 41
Study 9443116 — intervention group
Group type: EXPERIMENTAL
Intervention: High-meat group (HMG)
Number of subjects: 41
Study 9443116 — intervention group
Group type: COMPARATOR
Intervention: Low-meat group (LMG)
Number of subjects: 41
Study 9443116 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 8059045 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (group A)
Number of subjects: 80
Study 8059045 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group B)
Number of subjects: 80
Study 3143436 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative collaborative care with supervision by a geriatrician
Number of subjects: 108
Study 3143436 — intervention group
Group type: COMPARATOR
Intervention: Routine orthopaedic care
Number of subjects: 108
Study 29486879 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TIVA (15.0 ± 4.7 mg/kg/h)
Number of subjects: 30
Study 29486879 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (mean EtISO of 1.12 ± 0.15%)
Number of subjects: 30
Study 29486879 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TIVA
Number of subjects: 30
Study 29486879 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 28146606 — intervention group
Group type: EXPERIMENTAL
Intervention: 4β-hydroxycholesterol (4βOHC)
Number of subjects: 79
Study 26678437 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention for falling (specific details not provided)
Number of subjects: 6668
Study 26678437 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritization for falling (specific details not provided)
Number of subjects: 6668
Study 26678437 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent falls in the past year
Number of subjects: 6668
Study 26678437 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe fear-of-falling
Number of subjects: 6668
Study 26678437 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a walking aid
Number of subjects: 6668
Study 23652951 — intervention group
Group type: EXPERIMENTAL
Intervention: HP802‐247 (5M cells/mL) applied weekly
Number of subjects: 0
Study 23652951 — intervention group
Group type: COMPARATOR
Intervention: Bacitracin ointment applied daily
Number of subjects: 0
Study 20450412 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of oral micronized 17β-estradiol daily for 2 years
Number of subjects: 222
Study 20450412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 19876415 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus-extraction catheters during carotid artery stenting
Number of subjects: 43
Study 19876415 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery stenting with distal embolic protection devices (DEPs) without prophylactic thrombus aspiration
Number of subjects: 43
Study 17113932 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback
Number of subjects: 10
Study 17113932 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 10
Study 17113932 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 10
Study 17113932 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 15488112 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual format of guided self‐change (I‐GSC)
Number of subjects: 213
Study 15488112 — intervention group
Group type: EXPERIMENTAL
Intervention: Family involved format of guided self‐change (F‐GSC)
Number of subjects: 213
Study 15488112 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of I‐GSC or F‐GSC
Number of subjects: 213
Study 15488112 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 213
Study 11101175 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide at doses ranging from 200 to 1600 microg administered twice daily for 12 to 20 weeks.
Number of subjects: 1255
Study 11101175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study 9299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily for 10 days
Number of subjects: 0
Study 9299668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 8394191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (0.625 mg/day)
Number of subjects: 60
Study 8394191 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 micrograms/day)
Number of subjects: 60
Study 3538107 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 137
Study 3538107 — intervention group
Group type: EXPERIMENTAL
Intervention: phenelzine
Number of subjects: 137
Study 3538107 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137
Study 30397984 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-dose isotretinoin (20 mg/day)
Number of subjects: 30
Study 30397984 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional high-dose isotretinoin (0.5 mg/kg/day)
Number of subjects: 30
Study 30397984 — intervention group
Group type: EXPERIMENTAL
Intervention: Both isotretinoin regimens
Number of subjects: 30
Study 30397984 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 30
Study 30397984 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment dermcidin levels
Number of subjects: 30
Study 26869496 — intervention group
Group type: EXPERIMENTAL
Intervention: Open wedge osteotomy and fixation with plate (Hemax)
Number of subjects: 45
Study 26869496 — intervention group
Group type: COMPARATOR
Intervention: Crescentic osteotomy and fixation with a 3 mm cannulated screw
Number of subjects: 45
Study 24779421 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile suggesting the fellow student was 'high achieving'
Number of subjects: 0
Study 24779421 — intervention group
Group type: COMPARATOR
Intervention: Profile suggesting the fellow student was more normative in achievements
Number of subjects: 0
Study 24779421 — intervention group
Group type: EXPERIMENTAL
Intervention: High social anxiety
Number of subjects: 0
Study 23013946 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated poliacrylonitrile AN69ST® membrane without systemic anticoagulation
Number of subjects: 6
Study 23013946 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone HF80® dialyzer with standard anticoagulation (nadroparin)
Number of subjects: 6
Study 23013946 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone HF80® dialyzer with nadroparin
Number of subjects: 6
Study 23013946 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated poliacrylonitrile AN69ST® membrane
Number of subjects: 6
Study 21661459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration cytology (FNAC)
Number of subjects: 40
Study 21661459 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological examination
Number of subjects: 40
Study 21661459 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 40
Study 17561739 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative care
Number of subjects: 0
Study 17561739 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 0
Study 16285357 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel chemotherapy every three weeks combined with prednisone
Number of subjects: 0
Study 16285357 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone plus low-dose prednisone
Number of subjects: 0
Study 11977645 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeloda (capecitabine) at a dose of 2,510 mg/m2/d, bid, for two weeks followed by one week rest as one cycle.
Number of subjects: 22
Study 11977645 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeloda (capecitabine) in patients who had failed previous chemotherapy with taxanes and/or anthracycline.
Number of subjects: 22
Study 11977645 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions to Xeloda.
Number of subjects: 22
Study 10563531 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 31
Study 10563531 — intervention group
Group type: COMPARATOR
Intervention: Silymarin (Control)
Number of subjects: 31
Study 7878283 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (5 to 10 mg)
Number of subjects: 50
Study 7878283 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP) (5 to 20 mg)
Number of subjects: 50
Study 7878283 — intervention group
Group type: COMPARATOR
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 50
Study 2086208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified cereal (bovine haemoglobin concentrate, Fe: 14 mg/100 g of powder)
Number of subjects: 188
Study 2086208 — intervention group
Group type: COMPARATOR
Intervention: Regular solid foods (cooked vegetables and meat)
Number of subjects: 188
Study 2086208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified cereal with additional supplementation of 45 mg Fe for 90 days
Number of subjects: 188
Study 457522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate (NaNO3) aerosol inhalation
Number of subjects: 21
Study 457522 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) aerosol inhalation
Number of subjects: 21
Study 31099264 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercises three times a week for 12 weeks
Number of subjects: 89
Study 31099264 — intervention group
Group type: COMPARATOR
Intervention: General exercise protocol three times a week for 12 weeks
Number of subjects: 89
Study 29063244 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (0.5 mg daily)
Number of subjects: 157
Study 29063244 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1b (250 µg every other day)
Number of subjects: 157
Study 26463176 — intervention group
Group type: EXPERIMENTAL
Intervention: Community of Voices choir intervention
Number of subjects: 0
Study 26463176 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait 6 months to start the choir)
Number of subjects: 0
Study 23896477 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2336805 (≥10 mg single dose)
Number of subjects: 69
Study 23896477 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2336805 (various doses)
Number of subjects: 69
Study 23896477 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2336805 (with food)
Number of subjects: 69
Study 23896477 — intervention group
Group type: COMPARATOR
Intervention: GSK2336805
Number of subjects: 69
Study 22051229 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation (ORIF)
Number of subjects: 53
Study 22051229 — intervention group
Group type: COMPARATOR
Intervention: External Fixation
Number of subjects: 53
Study 22051229 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar Locking Plates
Number of subjects: 53
Study 22051229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Plates
Number of subjects: 53
Study 19151049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch (Synera, Rapydan)
Number of subjects: 82
Study 19151049 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine/prilocaine cream (EMLA)
Number of subjects: 82
Study 17142824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (support level set at 10 cm H(2)O)
Number of subjects: 32
Study 17142824 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 32
Study 15969850 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of the leaflet
Number of subjects: 230
Study 15969850 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of the leaflet plus incentive for systematic processing
Number of subjects: 230
Study 15969850 — intervention group
Group type: COMPARATOR
Intervention: No-leaflet control
Number of subjects: 230
Study 12211502 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment before 28 weeks of gestation
Number of subjects: 400
Study 12211502 — intervention group
Group type: COMPARATOR
Intervention: Periodontal treatment after delivery
Number of subjects: 400
Study 10480624 — intervention group
Group type: EXPERIMENTAL
Intervention: Q allele carriers (n = 41, 39 KQ and 2 QQ)
Number of subjects: 121
Study 10480624 — intervention group
Group type: COMPARATOR
Intervention: cultured skin fibroblasts from KQ versus KK subjects
Number of subjects: 121
Study 10480624 — intervention group
Group type: EXPERIMENTAL
Intervention: KQ subjects (n = 11)
Number of subjects: 121
Study 8686815 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with low dose fentanyl
Number of subjects: 70
Study 8686815 — intervention group
Group type: COMPARATOR
Intervention: Midazolam with high dose fentanyl
Number of subjects: 70
Study 1753612 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy alone (N=24)
Number of subjects: 77
Study 1753612 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy in combination with hyperbaric oxygenation (N=27)
Number of subjects: 77
Study 1753612 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy in combination with hemosorption (N=26)
Number of subjects: 77
Study 6802557 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose System (TPN with intravenous glucose)
Number of subjects: 15
Study 6802557 — intervention group
Group type: COMPARATOR
Intervention: Lipid System (TPN with 50% glucose + 50% intravenous fat)
Number of subjects: 15
Study 6802557 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose System
Number of subjects: 15
Study 6802557 — intervention group
Group type: COMPARATOR
Intervention: Lipid System
Number of subjects: 15
Study 31287725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D virtual world classroom (VW group)
Number of subjects: 215
Study 31287725 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom (RL group)
Number of subjects: 215
Study 29141663 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with quality assurance support
Number of subjects: 36
Study 29141663 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmark case radiotherapy planning
Number of subjects: 36
Study 29141663 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose distribution
Number of subjects: 36
Study 29141663 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation and QA processes
Number of subjects: 36
Study 25760874 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily or 15 mg if creatinine clearance was 30-49 ml/min)
Number of subjects: 0
Study 25760874 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted Vitamin K antagonists (VKAs)
Number of subjects: 0
Study 23432642 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder air-polishing (GPAP) for 5 sec in addition to oral hygiene instruction and non-surgical debridement.
Number of subjects: 24
Study 23432642 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical debridement and oral hygiene instruction (Control group).
Number of subjects: 24
Study 23432642 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control).
Number of subjects: 24
Study 22989394 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase 90 μg/kg IV bolus injection
Number of subjects: 848
Study 22989394 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase 70 and 90 μg/kg IV bolus injection
Number of subjects: 848
Study 22989394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848
Study 18829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel shrinkage
Number of subjects: 45